Intersection · Compounds × preprint

Compounds topics tagged preprint

Topics in Compounds carrying the tag preprint. Not yet peer reviewed. Labelled every time.

40 topics

Topic	Participants	Replies	Views	Activity
What TRIUMPH is designed to answer, and why we should not pre-empt it retatrutide effect size TRIUMPH programme preprint Solved What TRIUMPH is designed to answer, and why we should not pre-empt it I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in…	+4	8	142	6h
Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry retatrutide randomised trial effect size preprint Solved Revisiting: Hepatic effects of glucagon receptor agonism: the mechanistic worry Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURMOUNT-OSA ( N Engl J Med ,…	+10	14	8.4k	16h
Stability of BPC-157 in solution: what has been measured — one year on needs a source observational data preprint BPC-157 On the subject in the title: Stability of BPC-157 in solution: what has been measured — one year on Working notes rather than a conclusion. Comparing STEP 2 ( Lancet , 2021) with STEP 1 ( N Engl J Med , 2021)…	+84	98	7.8k	18h
Why retatrutide discussion here is more cautious than elsewhere — one year on TRIUMPH programme effect size preprint retatrutide Asking directly, because I could not find a straight answer: Why retatrutide discussion here is more cautious than elsewhere — one year on Session topic: PIONEER 6 ( N Engl J Med , 2019). Please read it…	+92	97	3.6k	20h
Publication patterns in the BPC-157 literature, examined preprint BPC-157 TB-500 needs a source Solved Posting this under the heading it deserves: Publication patterns in the BPC-157 literature, examined Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in support of…	+40	45	3.4k	21h
Retatrutide mass and identity: what a report should show TRIUMPH programme preprint retatrutide effect size Solved Posting this under the heading it deserves: Retatrutide mass and identity: what a report should show Everything below is what sits behind that. Comparing SURMOUNT-4 ( JAMA , 2024) with STEP 4 ( JAMA , 2021)…	+22	27	872	22h
What would change my mind about repair peptides: a specific answer TB-500 needs a source preprint Under review What would change my mind about repair peptides: a specific answer — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURMOUNT-4 ( JAMA , 2024). Please…	+26	30	1.1k	23h
BPC-157: what the rodent literature actually shows, and what it does not — does this still hold? observational data needs a source BPC-157 TB-500 Solved The question in the title: BPC-157: what the rodent literature actually shows, and what it does not — does this still hold? I will give what I have already checked below so nobody repeats it. I have seen…	+6	10	3.1k	1d
Why the absence of controlled human data on BPC-157 matters more than people admit needs a source BPC-157 preprint Solved Why the absence of controlled human data on BPC-157 matters more than people admit — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing STEP 8 ( JAMA , 2022) with…	+60	66	16k	1d
Follow-up: The retatrutide phase 2 obesity paper, read closely retatrutide randomised trial preprint effect size The retatrutide phase 2 obesity paper, read closely — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not think it…	+19	23	16k	2d
Revisiting: Why the absence of controlled human data on BPC-157 matters more than people admit observational data TB-500 BPC-157 preprint Solved Revisiting: Why the absence of controlled human data on BPC-157 matters more than people admit Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURPASS-4 ( Lancet ,…	+50	55	7.8k	2d
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction retatrutide preprint randomised trial effect size Solved The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction I will give what I have already checked below so nobody repeats it. Comparing LEADER ( N Engl J Med…	+43	47	19k	2d
Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? needs a source preprint BPC-157 Analytical identity of BPC-157: a 15-mer with a simple mass — does this still hold? — that is the question, and I have not found it answered plainly anywhere I have looked. Session topic: SURPASS-2 ( N Engl J…	+28	33	1.6k	1mo
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on preprint retatrutide TRIUMPH programme randomised trial Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen SURPASS-2 (…	+3	7	1k	2mo
Why retatrutide discussion here is more cautious than elsewhere randomised trial effect size retatrutide preprint Solved Why retatrutide discussion here is more cautious than elsewhere I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURMOUNT-OSA ( N Engl J Med , 2024) cited…	+7	12	7.7k	2mo
Oral versus injected administration claims for BPC-157 BPC-157 observational data preprint TB-500 Oral versus injected administration claims for BPC-157 — setting out what I have, and where I think it stops being reliable. I have seen FLOW ( N Engl J Med , 2024) cited in support of a claim I do not think…	+20	24	47k	4mo
Reading a preclinical wound-healing model and its relevance to a human tendon — a second dataset observational data preprint BPC-157 Reading a preclinical wound-healing model and its relevance to a human tendon — a second dataset — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016)…	+64	69	27k	4mo
How to read a phase 2 result without treating it as a phase 3 result — what changed since TRIUMPH programme randomised trial preprint Solved Asking directly, because I could not find a straight answer: How to read a phase 2 result without treating it as a phase 3 result — what changed since Session topic: STEP 2 ( Lancet , 2021). Please read it…	+25	35	568	6mo
Retatrutide's phase 2 heart-rate signal and how to think about it randomised trial preprint TRIUMPH programme retatrutide On the subject in the title: Retatrutide's phase 2 heart-rate signal and how to think about it Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019) cited in support of a claim…	+19	23	20k	7mo
How to read a phase 2 result without treating it as a phase 3 result randomised trial preprint effect size TRIUMPH programme The question in the title: How to read a phase 2 result without treating it as a phase 3 result I will give what I have already checked below so nobody repeats it. Session topic: FLOW ( N Engl J Med , 2024).…	+36	40	35k	7mo
Follow-up: Retatrutide phase 2 in type 2 diabetes: the Lancet paper retatrutide effect size TRIUMPH programme preprint Retatrutide phase 2 in type 2 diabetes: the Lancet paper Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a claim I…	+1	5	31k	8mo
Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on retatrutide preprint randomised trial Solved Closed The question in the title: Why a glucagon receptor agonist in a weight-loss compound is not a contradiction — one year on I will give what I have already checked below so nobody repeats it. Comparing STEP 4 (…		4	3.7k	10mo
Second pass at: Triple agonism: additive, synergistic, or neither? TRIUMPH programme effect size retatrutide randomised trial Solved Under review Second pass at: Triple agonism: additive, synergistic, or neither? — that is the question, and I have not found it answered plainly anywhere I have looked. I have seen STEP 8 ( JAMA , 2022) cited in support…	+114	120	1.4k	10mo
BPC-157: what the rodent literature actually shows, and what it does not observational data preprint BPC-157 needs a source BPC-157: what the rodent literature actually shows, and what it does not — setting out what I have, and where I think it stops being reliable. I have seen LEADER ( N Engl J Med , 2016) cited in support of a…	+44	48	3k	10mo
Analytical identity of BPC-157: a 15-mer with a simple mass BPC-157 observational data needs a source preprint Analytical identity of BPC-157: a 15-mer with a simple mass Writing it up because I had to work it out twice and would rather nobody else did. Comparing SURMOUNT-OSA ( N Engl J Med , 2024) with STEP 2 (…	+3	7	5.2k	10mo
The retatrutide phase 2 obesity paper, read closely preprint effect size TRIUMPH programme Posting this under the heading it deserves: The retatrutide phase 2 obesity paper, read closely Everything below is what sits behind that. Session topic: STEP 8 ( JAMA , 2022). Please read it before posting;…		2	65k	10mo
[2026 update] What we do not know about retatrutide, listed explicitly TRIUMPH programme preprint effect size randomised trial Wiki What we do not know about retatrutide, listed explicitly — that is the question, and I have not found it answered plainly anywhere I have looked. Comparing SCALE ( N Engl J Med , 2015) with STEP 2 ( Lancet ,…	+79	83	952	11mo
TB-500 and thymosin beta-4: the fragment versus the protein observational data TB-500 BPC-157 preprint TB-500 and thymosin beta-4: the fragment versus the protein Writing it up because I had to work it out twice and would rather nobody else did. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a…	+107	118	22k	11mo
Triple agonism: additive, synergistic, or neither? retatrutide effect size preprint Solved The question in the title: Triple agonism: additive, synergistic, or neither? I will give what I have already checked below so nobody repeats it. Session topic: STEP 4 ( JAMA , 2021). Please read it before…	+71	80	38k	11mo
BPC-157: what the rodent literature actually shows, and what it does not — a second dataset TB-500 preprint observational data needs a source Solved On the subject in the title: BPC-157: what the rodent literature actually shows, and what it does not — a second dataset Working notes rather than a conclusion. I have seen PIONEER 6 ( N Engl J Med , 2019)…	+77	84	54k	11mo

Sponsored Sigma-Aldrich — certified reference materialsReference standards, analytical reagents and certified materials for method calibration. If you are validating a method, this is where the standard comes from.Reference standards →